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ABSTRACT 15 
Supramolecular hydrogels were synthesized using a bis-imidazolium based 16 
amphiphile, and incorporating chemically diverse drugs, such as the cytostatics 17 
gemcitabine hydrochloride and methotrexate sodium salt, the immunosuppressive 18 
drug tacrolimus, as well as the corticoid drugs betamethasone 17-valerate and 19 
triamcinolone acetonide, and their potential as drug delivery agents in the dermal 20 
treatment of Psoriasis was evaluated. The rheological behavior of gels was studied, 21 
showing in all cases suitable viscoelastic properties for topical drug delivery. Scanning 22 
electron microscopy (SEM) shows that the drugs included have a great influence on 23 
the gel morphology at the microscopic level, as the incorporation of gemcitabine 24 
hydrochloride leads to slightly thicker fibers, the incorporation of tacrolimus induces 25 
flocculation and spherical precipitates, and the incorporation of methotrexate forms 26 
curled fibers. 1H NMR spectroscopy experiments show that these drugs not only 27 
remain dissolved at the interstitial space, but up to 72% of either gemcitabine or 28 
methotrexate, and up to 38% of tacrolimus, is retained within the gel fibers in gels 29 
formed with a 1:1 gelator:drug molar ratio. This unique fiber incorporation not only 30 
protects the drug from degradation, but also importantly induces a Two Phase 31 
Exponential drug release, where the first phase corresponds to the drug dissolved in 32 
the interstitial space, while the second phase corresponds to the drug exiting from the 33 
gel fibers, and where the speed in each phase is in accordance with the 34 
physicochemical properties of the drugs, opening perspectives for controlled delivery. 35 
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Skin permeation ex vivo tests show how these gels successfully promote the drug 1 
permeation and retention inside the skin for reaching their therapeutic target, while in 2 
vivo experiments demonstrate that they decrease the hyperplasia and reduce the 3 
macroscopic tissue damage typically observed in psoriatic skin, significantly more than 4 
the drugs in solution. All these characteristics, beside the spontaneous and easy 5 
preparation (room temperature and soft stirring), make these gels a good alternative 6 
to other routes of administration for Psoriasis treatment, increasing the drug 7 
concentration at the target tissue, and minimizing side effects. 8 
Keywords—Nanopharmacotherapy, hydrogel, psoriasis, drug delivery, supramolecular chemistry, 9 
skin permeation, in vivo studies.  10 
INTRODUCTION 11 
Psoriasis has been classified as an immune-mediated inflammatory disease that alters the skin [1], affecting 12 
the patients generally with lesions in the form of red scaly plaques scattered over different parts of the body, 13 
such as, knees, elbows, back and scalp [2,3]. The chronic nature of the disease is most likely a consequence 14 
of a vicious cycle that involves different types of cells and cytokines. For instance, the hyperproliferation of 15 
epidermal cells (keratinocytes) secrete autoantigens such as the LL-37 peptide. These autoantigens induce a 16 
biochemical cascade involving the activation of immune cells such as dendritic and T cells, and their elevated 17 
secretion of cytokines, such as IL-20, IL-23, IL-17, IL-22, and IFN-γ. In turn, these cytokines promote the 18 
replication of keratinocytes [3–6]. Many efforts are being made to better understand the complexity of the 19 
disease pathogenesis [7], and this gradual understanding has led to the exploration of new therapeutic 20 
approaches [8–10]. Over the past few years, immunosuppressant drugs such as tacrolimus, or corticoid drugs 21 
such as triamcinolone acetonide and betamethasone 17-valerate, have been dermally applied for treatment of 22 
skin diseases, including Psoriasis [11,12]. As well, the cytostatic drug methotrexate has been clinically used 23 
as a parenteral or oral treatment for Psoriatic patients not responding to other treatments [3,13]. On the other 24 
hand, gemcitabine hydrochloride has been used as a systemic chemotherapeutic agent in different types of 25 
cancer, but has not been used as a treatment of Psoriasis. However; it has been reported that, when 26 
parenterally administered to cancer patients who were also affected by Psoriasis, a significant decrease of 27 
Psoriatic lesions was collaterally observed [14,15]. This observation is most probably a consequence of the 28 
drug’s ability to prevent the hyperproliferation of keratinocytes, therefore showing its potential in the 29 
treatment of this disease. Nevertheless, the long-term applicability of all these drugs, especially those 30 
parenterally administered, might be hampered by undesired side reactions. For this reason, the search of 31 
better drug delivery systems is of high interest. 32 
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Gels can be described as a soft material with viscoelastic behavior, composed of a solid-like network 1 
dispersed in a continuous liquid medium [16,17]. This kind of materials can be easily found in our quotidian 2 
life, where their properties are mainly determined by their composition and structure at microscopic level [18]. 3 
Due to the wide variety of gel types reported nowadays, these are generally classified by the crosslink nature 4 
(covalent or non-covalent) [19]. While covalent crosslinking gives rise to rigid structures suitable for devices 5 
that require mechanical resistance (e.g. contact lenses) [20], supramolecular aggregations grant these 6 
materials with a softer character, applicable in many biomedical fields including drug delivery [21]. 7 
Supramolecular gels are generally made of low molecular weight gelators (LMWG), which self-assemble 8 
under certain conditions to form the solid-like network. The progress made up to the present day has brought 9 
to the literature a wide range of compounds that can act as LMWG [17]. It has been reported that imidazolium 10 
compounds can show important host-guest supramolecular interactions, drastically changing their properties 11 
such as the pKa.[22] We have proven that dicationic bis-imidazolium amphiphiles can form supramolecular 12 
gels, which are able to effectively stabilize and release drugs from their matrix. Moreover, such drugs can be 13 
not only anionic [23,24], but also cationic [25], or neutral, as is the case of the lipophilic corticoids 14 
betamethasone 17-valerate or triamcinolone acetonide [26], therefore proving their potential as delivery 15 
systems for topical application.  16 
In the present work, we tested the ability of the dicationic imidazolium-based amphiphile 1·2Br (Figure 1) 17 
to form gels in presence of drugs which are suitable in the treatment of Psoriasis. Such drugs include  the 18 
previously studied betamethasone 17-valerate and triamcinolone acetonide, as well as the cytostatic or 19 
immunosuppressant drugs gemcitabine hydrochloride, tacrolimus, or methotrexate sodium salt. Gels formed 20 
were extensively characterized, from their morphology at the microscopic level to their rheological behavior. 21 
Moreover, their ability to release these drugs in vitro, as well as their ability to permeate the drugs through 22 
human skin ex-vivo, was studied. In addition, the amount of drug that can be retained inside the skin after 23 
topical application was assessed, as it is where they perform their therapeutic activity. Finally, in-vivo 24 
experiments in mice showed their efficacy on inhibiting the hyperplasia and tissue degeneration characteristic 25 
in Psoriasis. 26 
 27 
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  1 
Figure 1. Chemical structures of 1·2Br, tacrolimus, methotrexate sodium salt, gemcitabine hydrochloride, triamcinolone acetonide and betamethasone 17-2 
valerate. 3 
 4 
 5 
EXPERIMENTAL SECTION 6 
Materials 7 
All reagents were of analytical grade and were used without further purification processes. Methotrexate, 8 
tacrolimus, gemcitabine hydrochloride, sodium dodecyl sulfate and 12-O-Tetradecanoylphorbol 13-acetate 9 
(TPA) were purchased from Sigma (Germany). Betamethasone 17-valerate and triamcinolone acetonide were 10 
purchased from Acofarma (Spain). Paraffin film (Parafilm®) was purchased from Sigma (Germany). Digital 11 
caliper was purchased from Truper (Mexico). 12 
Gelling agent 1,3-bis[(3-octadecyl-1-imidazolio)methyl] benzene dibromide (1·2Br) was synthetized as 13 
reported previously.[27]  14 
Solvents and buffers: water was always used 18mΩ grade from a MilliQ® equipment. Ethanol, acetone 15 
(analytical grade), deuterium oxide 99% and methanol-d4 99% were purchased from Sigma (Germany). 16 
Phosphate buffer saline (PBS) (tablets) was purchased from Sigma (Germany) and prepared as indicated by 17 
the manufacturer. 18 
Triamcinolone acetonide Betamethasone 17-valerate
Gemcitabine hydrochloride Methotrexate sodium salt
1·2Br Tacrolimus
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 1 
Methods 2 
1) Gel Preparation 3 
Gels were always prepared by dissolving compound 1·2Br in ethanol by means of a sonicator prior to the 4 
slowly addition of water as the anti-solvent. Final concentration of 1·2Br in gels was 5 mg/mL unless stated 5 
otherwise. The mixtures were carefully stored in closed vials to prevent solvent evaporation and left to stand 6 
without disturbance at room temperature for gel formation.  7 
Gels incorporating a drug were always prepared by first dissolving the drug in either water or ethanol. For 8 
gels with tacrolimus (1·tacrolimus), betamethasone 17-valerate (1·betamethasone), or triamcinolone 9 
acetonide (1·triamcinolone), the drug was first dissolved in ethanol, the gelator 1·2Br was added to the 10 
solution in solid and sonicated until complete solution was observed. Water was added for completing the 11 
gelation process. For gels with gemcitabine hydrochloride (1·gemcitabine), drug was dissolved in water and 12 
was mixed with an ethanolic solution of gelator 1·2Br for completing gelation. For gels with methotrexate 13 
sodium sat (1·methotrexate), a concentrated aqueous stock solution of methotrexate sodium salt was first 14 
prepared by adding 1 M NaOH to an aqueous suspension of methotrexate, in a 2:1 molar ratio 15 
(NaOH:methotrexate), in order to deprotonate both carboxyl groups from methotrexate molecule and assure 16 
its water solubility. Finally, a dilution to the desired drug concentration was made in water, and an ethanolic 17 
solution of the gelator 1·2Br was added to complete the gelation process. A fresh stock solution of 18 
methotrexate sodium salt was prepared every time gels were formed. 19 
2) Influence of drug concentration in gel formation 20 
In order to choose the optimal gel composition, 2 mL of each gel with four different final drug 21 
concentrations were prepared (1, 2.5, 5 and 10 mg/mL). For the gel with gemcitabine hydrochloride, a 22 
solution of 1·2Br (10 mg) in ethanol (1 mL) was mixed with a solution of gemcitabine hydrochloride (2, 5, 23 
10 or 20 mg) in water (1 mL). For the gel with tacrolimus, 1·2Br (10 mg) was added to a solution of 24 
tacrolimus (2, 5, 10 or 20 mg) in ethanol (1 mL) and was sonicated until dissolved. Finally, 1 mL of distilled 25 
water was added in order to complete the gelation process. Gels with methotrexate sodium salt were prepared 26 
by mixing an aqueous solution of methotrexate sodium salt (2, 5, 10 and 20 mg of methotrexate) (1 mL), 27 
prepared from the methotrexate sodium salt stock solution, with a solution of 1·2Br (10 mg) in ethanol (1 28 
mL). The optimal gel composition for gels 1·betamethasone and 1·triamcinolone was determined 29 
according to [26]. 30 
Gelation time was measured by means of a tapping-and-tilting method. Briefly, upon mixing ethanolic and 31 
aqueous solutions, closed vials were softly tapped at certain intervals, in order to observe the vibration of the 32 
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liquid surface. The progressive decrease in the vibration of the surface indicated an increase in viscosity due 1 
to gelation. Finally, gelation was confirmed by tilting the vial to observe the sample does not flow. 2 
3) Drug incorporation into gel fibers 3 
Retention of the drug beneath the gel fibers was determined by 1H NMR spectroscopy using a Varian 400 4 
MHz NMR.  5 
For estimating the proportion of either methotrexate sodium salt or gemcitabine hydrochloride incorporated 6 
in the gel fibers, two solutions containing equal amounts of drug (2.8 mg, 8.28 µmol) were prepared in two 7 
different tubes (A and B), using 0.75 mL of deuterium oxide (D2O), and a 
1H NMR spectrum of each sample 8 
was recorded (Record 1). Then, 0.75 mL of deuterated methanol (CD3OD) with 1·2Br (7.5 mg, 8.28 µmol) 9 
was added to tube A, while in tube B just the 0.75 mL of CD3OD was added. Agitation of both tubes was 10 
necessary in order to ensure a proper homogenization. Gel was formed in tube A, while tube B remained in 11 
solution. 1H NMR spectrum of each sample was recorded.  12 
For estimating the proportion of tacrolimus incorporated, two solutions containing equal amounts of drug 13 
(6.7 mg, 8.28µmol) were prepared in two different tubes (A and B), using 0.75 mL of deuterated methanol 14 
(CD3OD), and 
1H NMR spectrum of each sample was registered. Then, 1·2Br (7.5 mg, 8.28 µmol) was added 15 
to tube A and dissolved. Subsequently 0.75 mL of deuterium oxide (D2O) were added to both tubes and 16 
mixed. Gel was formed in tube A, while tube B remained in solution. 1H NMR spectrum of each sample was 17 
recorded.  18 
4) Rheological measurements  19 
Rheological tests of gels 1·2Br, 1·gemcitabine, 1·tacrolimus and 1·methotrexate were performed using 20 
a a Haake Rheostress1 rheometer connected to a Thermo Haake Phoenix II + Haake C25P temperature 21 
control circulating bath, previously set to 32ºC during the whole experiment, and equipped with parallel plate 22 
geometry (Haake PP60 Ti, 60 mm of diameter, 2 mm gap between plates). In order to know the viscoelastic 23 
behavior of different gels, oscillation rheology testing was performed. Gels were formed in a 3.5 cm-diameter 24 
polystyrene plate, having a total volume of 14 mL, at a 5 mg/mL concentration of 1·2Br. For the drug-loaded 25 
gels, a drug concentration of 2.5 mg/mL was used, according to the optimal gel composition chosen. Prepared 26 
gels were always kept at room temperature overnight before study. Oscillation amplitude tests were 27 
performed by increasing a shear stress from 0.01 to 100 Pa at a constant frequency of 1 Hz, to determine the 28 
linear viscoelastic region (LVR). Oscillation frequency tests were performed by increasing the frequency 29 
from 0.01 to 10 Hz, at a constant amplitude of 0.5 Pa for being within the LVR. Storage modulus (G’) and 30 
loss modulus (G”) were determined in both tests, which are defined as: 𝐺′ =  
𝜏0
𝛾0⁄  cos 𝛿 𝐺
′′ =  
𝜏0
𝛾0⁄  sin 𝛿 31 
(where 𝜏0 and 𝛾0 are the amplitudes of stress and strain, respectively, and 𝛿 is the phase shift between them). 32 
Software Haake RheoWin®Job Manager V.3.3 and RheoWin®Data Manager V.3.3 (Thermo Electron 33 
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Corporation, Karlsruhe, Germany) were used to carry out the test and analysis of the obtained data, 1 
respectively. 2 
5) Scanning electron microscopy (SEM) 3 
Gels 1·gemcitabine, 1·tacrolimus and 1·methotrexate were prepared using a drug concentration of 2.5 4 
mg/mL, according to the optimal gel composition determined, and were mounted on SEM stubs (carbon 5 
adhesive), dried using a N2 current and coated with a sputtered thin film of gold. SEM images were acquired 6 
in a Jeol JSM-7100F SEM at 10 kV accelerating voltage at the Centres Científics i Tecnológics de la 7 
Universitat de Barcelona (CCiTUB). Images were taken at magnifications of 3000x, 10000x and 30000x. 8 
6) Drug release studies 9 
Drug release studies were performed using gels 1·gemcitabine, 1·tacrolimus and 1·methotrexate, in a 10 
Microette diffusion test system (Microette plus-Hanson Research) following previously reported 11 
methodologies [28,29]. Briefly, vertically assembled Franz-type diffusion cells (Crown Glass) (2.54 cm2 12 
diffusion area) as well as dialysis membranes (CelluSep T3 dialysis membrane, MWCO 12,000–14,000 Da, 13 
MFPI, USA), were used. Cells were equipped with a circulating bath previously set to 32 ºC for being the 14 
temperature of the skin. For 1·gemcitabine and 1·methotrexate release experiments, clean and dry cells 15 
were filled with 10 mM PBS pH 7.4 in the receptor chamber, whereas a mixture of ethanol:water (7:3) was 16 
used for tacrolimus, always complying SINK conditions [30]. The dialysis membranes were previously 17 
hydrated with the receptor solution and were mounted between the matched donor and the receptor 18 
compartment. Finally, a known amount of gel (≈0.3 g) was placed on the membrane surface in the donor 19 
compartment. All Franz cell openings including donor top and receptor arm were occluded with paraffin film 20 
to prevent evaporation. The receptor compartment was stirred at a constant speed using a magnetic stirrer. 21 
Sample volumes (300 µL) were taken at certain intervals and stored at -20 ºC for further analysis. Samples 22 
taken were immediately replaced by fresh receptor medium in order to maintain a constant volume and assure 23 
SINK conditions. All experiments were performed by triplicate for over 75 h. Drug concentration in samples 24 
was determined by HPLC.  25 
7) Skin permeation studies 26 
Human excised skin was obtained during abdominal plastic surgery on a 40-year-old Caucasian female with 27 
informed consent and appropriate institutional ethical approval. Full sections of 0.4 mm thickness containing 28 
the epidermis and part of the dermis were separated by means of an electric dermatome and stored at −20°C 29 
until required. Ex vivo human skin permeation experiments were conducted following a protocol similar to 30 
that in drug release section, but replacing the dialysis membranes by the skin sections with the stratum 31 
corneum facing the donor compartment according to guidelines [31,32]. Gels 1·gemcitabine, 1·tacrolimus, 32 
1·methotrexate, 1·betamethasone and 1·triamcinolone were introduced into the donor chamber in contact 33 
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with the epidermal side of the skin. The experiment was conducted over 27 h in order to prevent damage of 1 
the biological material. Samples (300 µL) from the receptor chamber were withdrawn at appropriate time 2 
intervals and stored at -20 ºC for further HPLC analysis, and the withdrawn volume was immediately replaced 3 
by receptor solution. All skin permeation studies were done by triplicate.  4 
8) Drug extraction from the skin 5 
At the end of the permeation study, the skin was cleaned with a gauze soaked in a 0.05% solution of sodium 6 
dodecyl sulfate and rinsed with water accurately. Then the skin outside of the permeation area was cut off 7 
and the permeation area was perforated with a needle, weighed, immersed in 1 mL of its corresponding 8 
receptor medium, and sonicated during 20 minutes in order to extract the drug from the skin. The resulting 9 
solutions were stored at -20 ºC for further HPLC analysis.  10 
9) Drug recovery experiments 11 
In order to know the maximum amount of drug that can be extracted from the skin, 2.5 mg/mL drug 12 
solutions (methotrexate sodium salt, or gemcitabine hydrochloride or tacrolimus or betamethasone 17-13 
valerate or triamcinolone acetonide) were prepared. An aliquot of each drug solution was stored at -20 ºC 14 
(original solution). Slices of skin were incubated separately inside Eppendorf tubes filled with a second 15 
aliquot of each drug solution for 24 hours at 32 ºC. Afterwards, the skin was taken out and the solution was 16 
stored at -20 ºC (after-incubation solution). Drug was extracted from the skin following the same protocol 17 
(Drug extraction from the skin) and the resulting solution was stored at -20 ºC (extraction solution). Drug 18 
concentrations of all samples were determined by HPLC. The drug retained inside the skin (absorbed by the 19 
skin) was obtained from the difference between original and after-incubation solutions. The recovery factor 20 
was calculated as the drug extracted divided by the drug retained inside the skin. 21 
10) HPLC determination 22 
The HPLC system used consisted of a Waters 2695 pump + injector, with a 2996 Photo Diode Array, 23 
equipped with an Ultrabase® 100 Å, 5 µm pore, ODS2 column (150 mm X 4.6 mm) from AKADY® 24 
Cromatográfica (Barcelona). Analytical methods used were previously validated.  25 
For the analysis of tacrolimus, the aqueous phase consisted of 40 mM sodium acetate with 85 µL/L of acetic 26 
acid in MilliQ water (pH 6). The aqueous solution was filtered before use (Channel A). The organic phase 27 
consisted of methanol (HPLC grade) (Channel B). The mobile phase consisted of a mixture of Channel 28 
A:Channel B, at a flow rate of 1 mL/min, following a gradient starting at 30:70 at 0 min, to 0:100 at 10 min, 29 
kept until 15 min, to 30:70 at 16 min, and kept until 22 min for stabilizing the column. Samples were 30 
monitored and further analyzed at 205 nm wavelength.  31 
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For the analysis of gemcitabine, the mobile phase consisted of a mixture of water-methanol, at a flow rate 1 
of 1 mL/min, following a gradient starting at 95:5 at 0 min, to 10:90 at 4.5, to 95:5 at 5.5 min, and kept until 2 
10 min for stabilizing the column. Samples were monitored and further analyzed at 268 nm wavelength.  3 
For the analysis of methotrexate, the aqueous phase consisted of 40 mM sodium acetate with 85 µL/L of 4 
acetic acid in MilliQ water (pH 6). The aqueous solution was filtered before use (Channel A). The organic 5 
phase consisted of methanol (HPLC grade) (Channel B). The mobile phase consisted of a mixture of Channel 6 
A-Channel B, at a flow rate of 1 mL/min, following a gradient starting at 95:5 at 0 min, to 60:40 at 4.5 min, 7 
kept until 7 min, to 30:70 at 8 min, kept until 10 min, to 95:5 at 11 min, and kept until 15 min for stabilizing 8 
the column. Samples were monitored and further analyzed at 300 nm wavelength. 9 
Calibration curves of all drugs were analyzed, and concentrations of all samples were determined 10 
constructed on the basis of peak area measurements. 11 
11) Data processing 12 
For drug release, skin permeation, drug extraction from the skin, and recovery experiments, data obtained 13 
by HPLC were treated using Microsoft Excel®. For drug release experiments, cumulative percentage of drug 14 
released was plotted against time, and different non-linear regression models including Higuchi, Weibull, 15 
Korsmeyer-Peppas, One Phase- and Two Phase Exponential Association models were tested. The best fitting 16 
model was chosen by means of the R2 value, through which kinetic parameters were obtained for each type 17 
of gel. For skin permeation studies, cumulative amounts of drug permeated to the receptor chamber were 18 
plotted versus time, and linear regression analyses were performed for obtaining the kinetic parameters. All 19 
regressions (linear and non-linear) were performed using GraphPad Prism (version 3.00, GraphPad software, 20 
Inc., USA). 21 
12) In-vivo experiments 22 
Male Swiss CD-1 mice (20–25g) were purchased from Circulo ADN S.A. de C.V. (Mexico) and were 23 
subjected to a quarantine period of 7 days on arrival. The animals were housed in plastic cages with soft 24 
bedding with access to controlled diet and optional tap water. The temperature was kept at 24±1◦ C and the 25 
relative humidity was kept at 50–60%. Artificial lighting was used to provide 12h light and 12h dark every 26 
24h. The studies were conducted under a protocol in accordance with the Mexican Official Norm for Animal 27 
Care and Handling (NOM-062-ZOO-1999). 28 
Inflammation and hyperplasia was induced in groups of mice (n=6) by daily applying a solution of 12-O-29 
Tetradecanoylphorbol 13-acetate (TPA) (2.5 µg) in ethanol (5 µL) along ten days on both sides of the right 30 
ear, while applying only ethanol on the left ear (without TPA) as a Control(-) (healthy skin). At the same 31 
time, on days 2, 4, 6, 8 and 10, a treatment was applied to each group of mice on both sides of the right ear. 32 
Treatment applied was either gel 1·2Br or 1·betamethasone or 1·triamcinolone or 1·tacrolimus or 33 
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1·methotrexate, or a drug in solution betamethasone 17-valerate or triamcinolone acetonide or tacrolimus 1 
in acetone, or methotrexate sodium salt in water, at the same concentrations than in gels. A group of mice 2 
was treated with the cream Celecrem® containing bethamethasone 17-valerate as the reference marketed 3 
product. A group of mice with daily TPA application on the right ear but without further treatment was taken 4 
as Control(+) (psoriatic skin). In addition, to evaluate the effect of the gel alone on healthy skin, a group of 5 
mice was treated with gel 1·2Br on the right ear without TPA application. At days 5, 8 and 11, pictures of 6 
the mice ears were taken, the main signs at the macroscopic level were observed, and the thickness of both 7 
ears was measured using a digital caliper. The thickness increase relative to Control(+) (psoriatic skin) was 8 
calculated according to the equation:  9 
 10 
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑖𝑛𝑐𝑟𝑒𝑎𝑠𝑒 (%)11 
=  
𝑇ℎ𝑖𝑐𝑘𝑛𝑒𝑠𝑠 𝑟𝑖𝑔ℎ𝑡 𝑒𝑎𝑟 [𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡] − 𝑇ℎ𝑖𝑐𝑘𝑛𝑒𝑠𝑠 𝑙𝑒𝑓𝑡 𝑒𝑎𝑟 [𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡]
𝑇ℎ𝑖𝑐𝑘𝑛𝑒𝑠𝑠 𝑟𝑖𝑔ℎ𝑡 𝑒𝑎𝑟 [𝐶𝑜𝑛𝑡𝑟𝑜𝑙(+)] − 𝑇ℎ𝑖𝑐𝑘𝑛𝑒𝑠𝑠 𝑙𝑒𝑓𝑡 𝑒𝑎𝑟 [𝐶𝑜𝑛𝑡𝑟𝑜𝑙(+)]
 100% 12 
 13 
 14 
 15 
  16 
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 1 
RESULTS AND DISCUSSION 2 
Optimization of gel formation  3 
The gelation behavior of supramolecular gelators is determined by different variables such as temperature, 4 
nature of solvent, and type and concentration of a drug in the gel [23,33]. As the cationic compound 1·2Br 5 
can form supramolecular gels in water-ethanol mixtures [26], here we evaluate the influence that the drugs 6 
gemcitabine hydrochloride, tacrolimus, and methotrexate sodium salt have on the gelling process, by 7 
observing the gelling time at different drug concentrations. The concentration of the gelator 1·2Br was 8 
maintained to 5 mg/mL for being the optimal for preparing gels for dermal drug delivery [23,26]. As it can 9 
be seen in Figure 2, the gel 1·2Br (without drug) is spontaneously formed in 10 min at room temperature, in 10 
accordance with previous observations [26]. As well, in the gels containing a drug, the increase of drug 11 
concentration results in an increase of the gelling time, independently of the type of drug. In the case of gel 12 
1·gemcitabine, the lowest drug concentration does not change the gelling time (10 min) as compared to gel 13 
without drug; however, the incorporation of either tacrolimus or methotrexate sodium salt at low 14 
concentrations seems to decrease the gelling time, forming gels in less than 10 min. For instance, at 2.5 15 
mg/mL drug concentration, gel 1·methotrexate is formed in 7 min, and gel 1·tacrolimus is formed in only 16 
3 min. Also, at the rest of the concentrations tested, gel 1·tacrolimus showed the fastest gelling. These results 17 
suggest that, when dissolved in the ethanol:water medium at low concentrations, either methotrexate or 18 
tacrolimus can act as a template, enhancing the nucleation to fiber formation. However, as the concentration 19 
of the drug is gradually increased, the steric hindrance of the drug molecules may impede the interaction 20 
between gelator-gelator molecules leading to the fibers growth, which explains the increase in gelation time. 21 
It is remarkable that this templating behavior is also observed with triamcinolone acetonide; however, it is 22 
not observed with other drugs such as gemcitabine, betamethasone, brimonidine, or AEBSF HCl, at the 23 
lowest drug concentrations tested [25,26].  24 
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 1 
Figure 2. Influence of drug concentration on gelling times for gels 1·2Br (), 1·gemcitabine (), 1·tacrolimus () and 1·methotrexate ().  2 
 3 
Optimum conditions for gel formation were therefore chosen considering a macroscopic homogeneous 4 
appearance, a sufficient drug concentration for therapeutic purposes, and a relatively fast gelling time (<20 5 
min). For instance, at the macroscopic level, no appreciable differences were observed between the different 6 
samples tested. Regarding gelling time, gels with a 2.5 mg/mL drug concentration or lower, formed gels in 7 
16 min, 3 min and 6 min, for 1·gemcitabine, 1·tacrolimus and 1·methotrexate, respectively. Regarding 8 
previously reported or commercially available formulations, it can be seen that Protropic® (tacrolimus 9 
ointment 0.3 mg/g or 1 mg/g), Positon® (ointment containing triamcinolone acetonide 2.5 mg/g), or other 10 
non-commercial products reported in literature (methotrexate ointments 1 mg/g to 30 mg/g) [34–36], show 11 
in all cases drug concentrations similar or lower than 2.5 mg/mL. Therefore, 2.5 mg/mL was chosen as the 12 
optimum drug concentration, at which gels were prepared in the rest of the experiments, unless stated 13 
otherwise. 14 
For gels including betamethasone 17-valerate (1·betamethasone) or triamcinolone acetonide 15 
(1·triamcinolone), optimum conditions had been determined as a 5 mg/mL drug concentration and a 5 16 
mg/mL gelator concentration. At these conditions, gel 1·betamethasone is formed in 10 min at room 17 
temperature, while 1·triamcinolone is readily formed in only 2 minutes [26]. 18 
 19 
Rheological analysis 20 
In order to evaluate the influence of the drug in the viscoelastic behavior of the gels, oscillatory analyses 21 
were carried out in gels 1·2Br, 1·gemcitabine, 1·tacrolimus and 1·methotrexate. Amplitude sweep tests 22 
show that the phase angle for all samples across the Linear Viscoelastic Region (LVR) was relatively low 23 
(17º - 20º). As well, G’ values are higher than G’’ ones in all samples. Results in these two parameters indicate 24 
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that the elastic (solid-like) component is prevalent over the viscous (fluid-like) one (Figure 3). Frequency 1 
sweep tests were performed in these gels at a constant shear stress of τ = 0.5 Pa for being within the LVR 2 
(See Supporting Information, Figure S 1), finding also that, independently of the frequency applied, G’ is 3 
higher than G’’, confirming the solid-like behavior of these gels [37,38]. 4 
 5 
Figure 3. Elastic modulus (G’), loss modulus (G’’) and phase angle (δ) as a function of shear stress: (A) 1·2Br (B) 1·gemcitabine, (C) 1·tacrolimus, and (D) 6 
1·methotrexate. 7 
Table 1. Critical stress values from gels with and without drug. 8 
Gel  Critical stress (Pa) 
1·2Br  0.415 
1·gemcitabine 0.576 
1·tacrolimus 1.237 
1·methotrexate 5.385 
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 1 
Amplitude tests also show the critical stress, which can be identified as a sharp drop in G’, and which is the 2 
minimum stress that overcomes the elasticity or inherent resistance to rupture within the sample. The 3 
resulting critical stress values (f = 1Hz) for each sample are shown in Table 1, where it can be seen that the 4 
elasticity of the material is increased when incorporating either of these drugs. For instance, gel 5 
1·gemcitabine is 1.38 times more resistant to rupture, gel 1·tacrolimus is almost 3 times more resistant, and 6 
gel 1·methotrexate is almost 13 times more resistant, than gel 1·2Br. Conversely, the incorporation of the 7 
neutral corticoid drugs betamethasone 17-valerate or triamcinolone acetonide, or other cationic or anionic 8 
drugs into gel 1·2Br, has resulted in a loss of elasticity.[26] Nevertheless, it is worth noticing that the 9 
incorporation of either drug (gemcitabine hydrochloride or tacrolimus or methotrexate sodium salt, or even 10 
triamcinolone acetonide or betamethasone 17-valerate[26]) always leads to gels that can be broken abruptly 11 
when critical stress is reached, which is optimum for a comfortable application on irritated skins. On the 12 
other hand, the softness of the material, as seen in the resistance to deformation (G’ and G’’ values) is also 13 
strongly influenced by the drug added. However, no direct relationship can be apparently observed between 14 
this property and drug molecular weight, charge, or amount of drug incorporated in fibers. For instance, the 15 
inclusion of either triamcinolone acetonide or tacrolimus does not change the resistance to deformation as 16 
compared to gel 1·2Br, while the addition of either betamethasone 17-valerate or gemcitabine hydrochloride 17 
makes it four-times softer, and while the addition of methotrexate sodium salt makes it eight-times more 18 
rigid.  19 
Drug incorporation into gel fibers 20 
1H NMR experiments were performed to know if gels formed with compound 1·2Br incorporate either 21 
gemcitabine hydrochloride or tacrolimus or methotrexate sodium salt dissolved in the interstitial space of the 22 
gel, or if they can even incorporate these drugs within gel fibers. For instance, when a 1H NMR spectrum is 23 
collected from a gel, signal only arises from species dissolved in the liquid trapped between the fibers, and 24 
intensity values of intra-molecular resonances depend upon the number of nuclei causing the signal [39]. 25 
Thus, as the total concentration of drug used to form the gel is known, it is possible to assess the proportion 26 
of drug that is trapped inside the gel fibers when the gel is formed. Indeed, results show that these three drugs 27 
are not only retained in the interstitial space of the gel but also beneath gel fibers. Experiments were 28 
performed at a 1:1 gelator:drug molar ratio for quantification purposes, finding that gel 1·2Br can incorporate 29 
up to 72% of either methotrexate or gemcitabine, and up to 38% of tacrolimus inside gel fibers (See 30 
Supporting Information, Figure S 2 to Figure S 4). As well, gel 1·2Br in presence of triamcinolone acetonide 31 
or betamethasone 17-valerate in a 1:1 molar ratio, entraps up to 54% and 65% of the drug inside the fibers, 32 
respectively [26].  33 
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Therefore, according to the optimum drug concentration (see Optimization of gel formation), when gels 1 
1·gemcitabine, 1·tacrolimus, and 1·methotrexate are prepared with a 2.5 mg/mL drug concentration, 48% 2 
(1.19 mg/mL) of gemcitabine, 68% (1.69 mg/mL) of tacrolimus, and 72% (1.81 mg/mL) of methotrexate, 3 
should be incorporated inside the fibers. Similarly, when gels 1·triamcinolone and 1·betamethasone are 4 
formed with a 5 mg/mL drug concentration, 26% (1.29 mg/mL) of triamcinolone, and 34% (1.71 mg/mL) of 5 
betamethasone, should be entrapped in fibers [26]. 6 
Only a few examples of drugs incorporated inside fibers can be found in literature, but in all cases, either 7 
the fabrication process or the drug release shows drawbacks. For instance, fiber-incorporation has been 8 
achieved through electrospinning techniques in polymeric gels; nonetheless, the control of several parameters 9 
is required, both of the equipment (electric field, air velocity in spinning chamber, flow rate), and of the 10 
component that forms the fibers (dielectric constant, surface tension, and conductivity) [40–43]. On the other 11 
hand, the entrapment of a drug in the fibers of a supramolecular gel has been reported; however, it requires 12 
the previous covalent attachment of the drug to the gelator, and therefore its release depends on an enzymatic 13 
cleavage [44]. Instead, in almost the totality of the gels containing drugs, the drugs are dissolved in the 14 
interstitial space. For this reason, supramolecular gels formed with compound 1·2Br constitute a multiple 15 
advantage as a drug delivery system: a) the non-covalent bonds forming the fibers of the supramolecular gels 16 
makes them soft and therefore suitable for dermal application; b) the entrapment of the drugs in the fibers 17 
provides a reservoir, storing and protecting the drug from degradation; c) such entrapment  is non-covalent, 18 
making the release independent of the presence of enzymes; and d) the preparation of these drug-loaded gels 19 
is easy and fast, as it occurs spontaneously at room temperature in a few minutes. All these characteristics 20 
make these gels a promising material for controlled delivery.  21 
Scanning Electron Microscopy 22 
The incorporation of a drug can strongly influence the nanometric structure of gel 1·2Br fibers. For this 23 
reason, the role that played the incorporation of either gemcitabine hydrochloride, tacrolimus or methotrexate 24 
sodium salt on the xerogel structure was revealed by Scanning Electron Microscopy (SEM) and compared to 25 
that of 1·2Br alone.  26 
The xerogel of 1·2Br presents a packed structure with long cylindrical fibers around 140 nm in diameter 27 
(Figure 4, A, B), in agreement with previous observations [26].  28 
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 1 
Figure 4. SEM images of xerogels of (A,B) 1·2Br, (C,D) 1·gemcitabine, (E,F) 1·tacrolimus, and (G,H) 1·methotrexate. Scale bar represents 10 µm and 1 µm 2 
for the left and right images respectively. 3 
1·gemcitabine xerogel network is also formed by long fibers, though they seem to be slightly bigger in 4 
diameter (200 nm), and the spaces between the fibers seem to be slightly wider (Figure 4, C, D). It is 5 
interesting to mention that, as shown by 1H-NMR drug incorporation experiments, when gels are prepared 6 
with a 2.5 mg/mL, 52% of the drug remains dissolved at the interstitials; therefore, upon solvent evaporation 7 
in sample preparation, observations of drug precipitates in between the fibers would be expected. However, 8 
xerogel of 1·gemcitabine shows no drug precipitates, as compared to a solution of gemcitabine hydrochloride 9 
under the same conditions but without gelator, where needle-shaped crystals are found after drying the 10 
solvent (See Supporting Information, Figure S 5, A). This suggests that the gelator 1·2Br might be promoting 11 
gemcitabine hydrochloride to precipitate in nanometric structures that cannot be seen under the equipment 12 
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resolution. This behavior had been previously observed when incorporating another cationic drug 1 
(AEBSF·HCl) into gel 1·2Br.[25] Such important decrease in particle size is highly desirable for 2 
therapeutical purposes, as it increases the total drug surface area and thus the speed of dissolution for reaching 3 
the pharmacological target. 4 
On the other hand, xerogel 1·tacrolimus shows a heterogeneous structure composed by spherical drug 5 
precipitates adhered over the gel fibers (Figure 4, E, F). Acordingly, tacrolimus in ethanol:water (50:50) 6 
solution forms spherical amorphous precipitates when dried (See Supporting Information, Figure S 5, B), for 7 
which spherical precipitates in the xerogel most probably correspond to drug. This morphology had also been 8 
observed with gels incorporating betamethasone 17-valerate, which is also a neutral drug. Conversely, 9 
xerogels with triamcinolone acetonide, despite also being a neutral corticoid drug, show prismatic-shaped 10 
drug precipitates [26]. This suggests that the precipitation in amorphous spherical forms is probably promoted 11 
by higher lipophilicities, as both tacrolimus and betamethasone 17-valerate show logP values around 3.5, 12 
while triamcinolone acetonide shows a logP value of 2.5 (See Supporting Information, Table S 2). Also, the 13 
xerogel fibers of 1·tacrolimus show a wider dispersity in size as compared to 1·2Br, with diameters ranging 14 
from 170 nm to 1 µm, showing flocculation, where fibers stick together to form thicker fibers.  15 
Very differently, xerogel 1·methotrexate presents a characteristic morphology of curled single fibers of 16 
around 120 nm thick. Flocculation can also be observed, as the individual fibers attach longitudinally, 17 
forming thicker fibers varying from 250 to 500 nm in width. As well, bigger interstitial spaces are created by 18 
the fiber curls (Figure 4, G, H). Interestingly, an ethanol:water (50:50) solution of methotrexate sodium salt 19 
but without the gelator, after drying the solvent, shows precipitates also in the shape of curled fibers. A 20 
possible explanation of this behavior is that the majority of long chiral molecules bearing a stereocenter tend 21 
to form twisted aggregates [45–47]. Drug incorporation experiments show that, at a 2.5 mg/mL drug 22 
concentration, up to 72% of the drug in the gel is incorporated inside the fibers. Thus, as xerogels of 23 
1·methotrexate show a continuous curled morphology, some of these curls could possibly be comprised of 24 
drug exclusively, but some of them should be comprised of drug-loaded gel fibers. This shows that the 25 
methotrexate sodium salt incorporated inside the fibers is promoting an important change of the shape of the 26 
fibers, from a somehow straight shape, into a clearly curled one that provides wide interstitial areas.  27 
All these results not only confirm that changes among the guest substance lead to changes in gel 28 
morphology, as reported by other authors [48], but most importantly, these observations provide consistent 29 
explanations for the rheological behavior of gels. For instance, the entangled curled structure of 30 
1·methotrexate could explain both the higher elasticity (higher critical stress values) and the higher 31 
resistance to deformation (higher G’ and G’’ values) as compared to 1·2Br. Similarly, the wider fibers created 32 
in 1·tacrolimus might be responsible for the increase in elasticity.  33 
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Drug release studies 1 
In vitro release experiments of gels 1·gemcitabine, 1·tacrolimus and 1·methotrexate were performed to 2 
demonstrate that the gel 1·2Br matrix is able to release the drug incorporated in it, and that the release profile 3 
does not limit the permeation of the drug through the human skin. Cumulative percent of either gemcitabine 4 
or tacrolimus or methotrexate released from gel matrix over 3 days is shown in Error! Reference source 5 
not found.. As well, experimental data from release experiments of 1·betamethasone and 1·triamcinolone 6 
were taken from [26] and plotted in the figure for comparison purposes. Results from the release of gel 7 
1·tacrolimus show bigger variabilities as compared to the other gels, which is due to the lack of a 8 
chromophore group in tacrolimus molecule, making its detection under UV-absorbance HPLC more difficult. 9 
 10 
Figure 5. In vitro drug released (%)along time from gels (A) 1·gemcitabine, (B) 1·tacrolimus, (C) 1·methotrexate, (D) 1·betamethasone and (E) 11 
1·triamcinolone. Experimental data from 1·betamethasone and 1·triamcinolone were taken from [26]. Drug release in all cases followed a Two-Phase 12 
Exponential Association model. The first phase release is shown in dotted line, the second phase release is shown in dashed line, and the cumulative amount of 13 
drug released from both phases is shown in continuous line. (F) A comparative view is shown. Values represent Means ±SD (n=3).  14 
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Different models were fit within the release data using non-linear-least squared regression, while the best 1 
model was chosen by means of the R2 value. Gels 1·gemcitabine, 1·tacrolimus and 1·methotrexate best 2 
followed a Two-Phase Exponential Association model, which is described by the equation: 3 
𝑌 = 𝑌𝑚𝑎𝑥1(1 − 𝑒
−𝐾1 𝑡) +  𝑌𝑚𝑎𝑥2(1 − 𝑒
−𝐾2 𝑡)  4 
Where the total amount of drug released (Y) at a certain time (t), is the result of two exponential drug release 5 
processes occurring at the same time, each one at a certain speed (K), and with a maximum amount of drug 6 
released (Ymax). It has been reported that the morphology of the gel at the microscopic level is a main factor 7 
influencing the release profile; for example, an open-porous matrix morphology facilitates the drug diffusion, 8 
causing an initial burst [49–52]. However, in these supramolecular gels, the matrix morphology is not the 9 
only factor influencing the Two-Phase release behavior. Instead, the proportion of drug that is outside and 10 
inside the gel fibers is most probably the factor playing a major role. In this sense, the first phase, or faster 11 
drug release, might correspond to the drug that is dissolved in the interstitial space, and is released from the 12 
matrix by diffusion through the pores; while the second phase, or slower release, could correspond to the 13 
drug initially entrapped inside the fibers, which first exits to the interstitial space, and then diffuses through 14 
the pores.  15 
As shown in the drug incorporation experiments, in gels with a 2.5 mg/mL drug concentration, 16 
approximately 48% of gemcitabine, 72% of methotrexate, and 68% of tacrolimus should be inside the fibers, 17 
for which 52%, 28% and 32%, respectively, should be dissolved in the interstitial space of the gel. 18 
Accordingly, drug release experiments show that nearly 59% of gemcitabine, 41% of methotrexate, and 31% 19 
of tacrolimus can be released in the first phase, as can be seen by the Ymax1 values, and therefore in 20 
consonance with the drug dissolved in the interstitial space. Drug release parameters such as maximum drug 21 
released and speed constants are shown in Supporting Information (Table S 1). As the first phase release 22 
occurs by  diffusion through the solvent, the speed may be influenced by both the affinity of the drug for the 23 
medium, and the porosity of the gel matrix. Results show that both gemcitabine and methotrexate are released 24 
four-times faster than tacrolimus, as can be seen in the speed constant (K1) values, suggesting that the highly 25 
hydrophobic nature of tacrolimus, and its low water solubility, could influence a slower diffusion through 26 
the medium at interstitial space as compared to methotrexate and gemcitabine. Partition coefficient (LogP), 27 
water solubility values, and other drug physicochemical factors are shown in Supporting Information (Table 28 
S 2). 29 
In the second phase, in contrast, the three gels keep releasing drug at a significantly lower speed as 30 
compared to the first phase. It can be seen that nearly 7.3 µg of tacrolimus per hour per mL of gel can be 31 
released, while methotrexate is released at 3.8 µg h-1 mL-1, and gemcitabine at 1.5 µg h-1 mL-1. As the second 32 
phase occurs by diffusion through the gel fibers until reaching the interstitial space, the speed of release may 33 
be influenced by the concentration gradient between the fibers and the interstitials, as well as by the drug’s 34 
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affinity for both the fibers and the interstitial space. Hence, as the gelator molecule bears hydrophobic carbon 1 
chains, hydrophobic drugs may diffuse through the fibers to reach the interstitials, while highly hydrophilic 2 
drugs, once entrapped within the fibers, may be retained inside for longer periods by hydrophobic 3 
interactions. Accordingly, the hydrophobic structure of tacrolimus may be related with its faster release in 4 
the second phase, as compared to that of methotrexate and gemcitabine, which show a highly hydrophilic 5 
nature. 6 
This Two-phase release mechanism can also explain the release profile observed in gels 1·triamcinolone 7 
and 1·betamethasone. Although the release of these two gels has been described as a One-Phase Exponential 8 
Association model [26], it can indeed be described as a Two-Phase model, where the speed constants of the 9 
first (K1) and second (K2) phases are similar. According to the drug incorporation experiments, at a 5 mg/mL 10 
drug concentration, approximately 74% of triamcinolone acetonide and 66% of betamethasone 17-valerate 11 
should be dissolved in the interstitials. Besides, drug release experiments show that 91% of triamcinolone 12 
acetonide and 79% of betamethasone 17-valerate is released during a period of 12 hours [26]. 13 
Correspondingly, the release profiles of both drugs accurately comply a Two-phase exponential association 14 
model with R2 values of 0.99 and 0.98, respectively (See Supporting Information, Table S 1). This suggests 15 
that the 91% of triamcinolone released during the 12-hour period most probably corresponds to a first phase, 16 
where the drug dissolved at the interstitials (74%) is released, plus a second phase, where 17% of the drug 17 
exits from the fibers, both phases showing speed constants (K1=K2) of 0.25 h-1. Similarly, the 79% of 18 
betamethasone released during the first 12 hours might correspond to a first phase, where the drug dissolved 19 
in the interstitials (66%) is released, plus a second phase, where 13% of drug exits from the fibers, with speed 20 
constants of 0.3 h-1. These results are in accordance with the physicochemical properties of betamethasone 21 
17-valerate and triamcinolone acetonide, which may influence their faster release from the gel fibers as 22 
compared to the other drugs. For instance, the log P values of these two drugs show their moderate lipophilic 23 
nature, which explains their diffusion through the fibers. Subsequently, their solubility in water, up to three 24 
orders of magnitude higher than that of tacrolimus, could explain a higher affinity for the hydroalcoholic 25 
medium at the interstitials, promoting their exit from the fibers and further diffusion through the medium. 26 
This in turn creates a high concentration gradient between the fibers and the interstitials, promoting more 27 
drug release from the fibers. In contrast, the hydrophobicity of tacrolimus might explain its diffusion through 28 
the fibers; however, its low water solubility might retard its exit to the interstitials for further diffusion, 29 
creating a lower concentration gradient between the fibers and the interstitials, and promoting a slower 30 
release. 31 
All these results show that the unique capability of these supramolecular gels for incorporating drug beneath 32 
its own fibers, acts not only as a protection against drug degradation, but also makes this material a promising 33 
platform for controlled release, behaving selectively according to the nature of the drugs. 34 
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 1 
Skin permeation assays 2 
For the topical treatment of Psoriasis, two steps are crucial in the biochemical pathway of the disease, the 3 
autoimmune response, and the uncontrolled replication of keratinocytes in the epidermis stratum basale [4–4 
6]. Thus, when either methotrexate or gemcitabine are used for the treatment of dermatological diseases such 5 
as Psoriasis, their pharmacological target is located at the epidermis, as both drugs are intended to inhibit 6 
replication of cells of the stratum basale. In case of methotrexate, this occurs by inhibiting dihydrofolate 7 
reductase enzyme, while in case of gemcitabine, by inhibiting ribonucleotide reductase enzyme. In contrast, 8 
the pharmacological target of tacrolimus is located both at the dermis and the epidermis, where it inhibits the 9 
activity of immune cells such as T lymphocytes [14,53,54]. For this reason, in order to achieve their 10 
pharmacological efficacy, all of these drugs should penetrate the stratum corneum when topically applied, 11 
and ideally be retained beneath the epidermal and dermal layers. This would imply an increase in the 12 
concentration at the target tissue, and subsequently a raise in efficacy. Moreover, this retention would act as 13 
a drug depot, providing therapeutic activity for longer periods. 14 
For this reason, skin permeation experiments with gels 1·gemcitabine, 1·tacrolimus and 1·methotrexate 15 
at a drug concentration of 2.5 mg/mL were performed by placing them over human skin, using the same 16 
vertical diffusion cell system used in drug release experiments, but replacing the dialysis membrane for 17 
human skin, in order to quantitatively evaluate skin permeation parameters. Skin permeation experiments 18 
with gels 1·triamcinolone and 1·betamethasone had been performed before by us, showing that both drugs 19 
triamcinolone acetonide and betamethasone 17-valerate, when incorporated in gel 1·2Br, can penetrate the 20 
skin and remain retained beneath the epidermal and dermal layers, to a higher extent than existing products 21 
on the market Celecrem®, containing betamethasone 17-valerate, and Positon®, containing triamcinolone 22 
acetonide [26]. Nonetheless, due to the great biological variability between patients, permeation experiments 23 
with gels 1·betamethasone and 1·triamcinolone were also conducted in this work using human skin from 24 
the same patient for comparison purposes, using a drug concentration of 5 mg/mL for being the optimum 25 
concentration in these cases. At the end of the study, a skin extraction was performed to evaluate the amount 26 
of drug that was retained inside the tissue.  27 
Cumulative amounts of permeated drug per surface area [A] (µg/cm2) were plotted against time [t] (h) 28 
(Figure 6, A) and skin permeation parameters can be seen in detail in Supporting Information (Table S 3). 29 
From the drugs studied, neither gemcitabine nor tacrolimus were detected in the receptor medium, showing 30 
they were not able to permeate the skin completely, while the rest of the drugs did show complete permeation. 31 
The inability of gemcitabine and tacrolimus for permeating the skin is most probably a consequence of their 32 
physicochemical properties. Parameters such as partition coefficient (log P) (measure of the lipophilic nature) 33 
and molecular weight (MW) are commonly used for predicting the skin permeability of a drug, being those 34 
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compounds with a log P ranging from 1 to 3 and a MW under 500 g/mol the ones which should present good 1 
skin permeation.[55,56] Gemcitabine is therefore significantly more hydrophilic than the ideal range, 2 
whereas tacrolimus has a MW of 804 g/mol, much higher than the ideal size (See Supporting Information, 3 
Table S 2). 4 
 5 
Figure 6. (A) Cumulative amount of drug permeated across human skin along time, after application of either 1·betamethasone, 1·triamcinolone or 6 
1·methotrexate gel; no drug permeation was observed after application of gels 1·gemcitabine or 1·tacrolimus. Values represent Means±SD (n=5). A linear least 7 
squares regression was performed. A magnification showing the Tlag (X-intercept) is shown inside the frame. (B) A comparison of the Kp·10
3 values calculated 8 
from drug permeation parameters. (C) Total amount of drug retained beneath the skin (µg g-1 cm-2) after application of gels 1·betamethasone, 1·triamcinolone, 9 
1·gemcitabine, 1·tacrolimus or 1·methotrexate, calculated according to the drug extraction and recovery experiments. Values represent Means ±SD (n=5). (B-10 
C) Different lowercase letters represent significant differences (P<0.05). 11 
 12 
Gel 1·betamethasone showed the shortest lag-time (Tlag) (4.6 h), indicated by the time-axis intercept value 13 
(Figure 6, A), and representing the time needed before the drug completely permeates the skin into the 14 
receptor chamber, while both 1·triamcinolone and 1·methotrexate presented a similar Tlag (10.6 h) (See 15 
Supporting Information, Table S 3). 16 
The speed of drug permeation at the steady-state (transdermal flux), is calculated with the slope of the linear 17 
regression [JSS].[57] However, it is well known that the transdermal flux is dependent on the drug 18 
concentration in the donor compartment (in the formulation applied) [C0]. As gel 1·methotrexate has a drug 19 
concentration different than the other two gels, the permeability coefficient [Kp] (cm h
-1) was used as a 20 
suitable parameter for comparing the permeation from all the different formulations, as it is obtained by 21 
dividing the flux into C0. For instance, it can be seen that the Kp of 1·betamethasone is 28% higher than that 22 
of 1·triamcinolone (0.06·10-3±0.01·10-3 cm h-1 and 0.08·10-3±0.01·10-3 cm h-1respectively) (P<0.05), which 23 
is also in accordance with previously reported results [26]. On the other hand, the Kp of 1·methotrexate is 24 
four times slower than the other two gels (0.018·10-3±0.002·10-3 cm h-1) (P<0.001). A graphic comparison 25 
of Kp values can be seen in (Figure 6, B), and statistical analysis of Kp values is shown in Supporting 26 
Information (Table S 4). 27 
Considering the cytotoxicity of methotrexate as the intrinsic pharmacological mechanism, the possible 28 
systemic toxicity that the application of the gel 1·methotrexate may have, was determined by means of the 29 
1·betamethasone
1·triamcinolone
1·methotrexate
1·gemcitabine
1·tacrolimus
0 6 2412 18
D
ru
g
 p
e
rm
e
a
te
d
 (
µ
g
 c
m
-2
) 
0
2
8
4
6
10
A
D
ru
g
 r
e
ta
in
e
d
 (
µ
g
 g
-1
c
m
-2
) 
0
200
800
400
600
C
a
b
c,d
a,c
a,c,d,e
0.000
0.025
0.100
0.050
0.075
a
b
c
K
p
·1
0
3
(c
m
 h
-1
) 
B
Time (h) 
- 23 -  
concentration in plasma at steady state (Css). It has been previously reported that mild toxicity might be 1 
manifested only at concentrations in serum above 10-6 M [58]. In this case, when 1·methotrexate is applied 2 
on the skin, the maximum concentration in plasma (Css) that could be reached is around 0.086 µg/L 3 
(equivalent to 10-10 M), which is four-orders below toxic concentration, indicating that its topical application 4 
should not cause any undesired effects in other regions of the body. Cytotoxicity-calculation parameters are 5 
shown in Supporting Information (Table S 5).  6 
The amount of drug remaining inside the skin can be calculated by means of both extraction and recovery 7 
assays. The extraction assay is performed to quantify the amount of drug that can be extracted from the skin 8 
after the experiment, while the recovery assay is performed to determine the experimental yield of the 9 
extraction, that is to say, the fraction of drug that can be extracted out of the total amount of drug that is 10 
actually retained. Results in Figure 6, (C), show that when incorporated in gel 1·2Br, the five drugs under 11 
study are retained within the epidermis and outer dermis layers, which is optimum for the treatment of skin 12 
diseases such as Psoriasis. Percentage of recovery (recovery factor) and total amount of drug retained inside 13 
the skin, as well as the statistical analysis from these data, can be seen in Supporting Information (Table S 6 14 
and Table S 7). For instance, the highest retention was seen with 1·triamcinolone (605.4 ± 182.5 µg g-1 cm-15 
2), significantly higher than the rest of the gels (P<0.01 to P<0.001). On the other hand, the lowest retention 16 
was obtained with 1·betamethasone, (31.6 ± 7.9 µg g-1 cm-2). The high affinity of triamcinolone acetonide 17 
for the skin tissues is also reflected in the low percentage of recovery (9%) as compared to the rest of the 18 
drugs (above 27%).  19 
Drug retention with 1·methotrexate and 1·gemcitabine was slightly higher than that from 20 
1·betamethasone (P<0.05), while with 1·tacrolimus was significantly higher than that from 21 
1·betamethasone. As it can be seen, despite neither tacrolimus nor gemcitabine completely crossed the skin, 22 
both of them were able to penetrate the stratum corneum and keep retained inside the skin. 23 
 24 
In-vivo studies 25 
Several in vivo models have been developed to mimic the human pathology of Psoriasis, from complex 26 
immunological or genetic ones, to simple models reached by the repeated application of a substance such as 27 
imiquimod or 12-O-Tetradecanoylphorbol 13-acetate (TPA).[59–63] In this work, the repeated application 28 
of TPA along 10 days was used to induce the characteristic inflammation and hyperplasia seen in psoriatic 29 
skin [61], and the suitable gels were chosen for in vivo efficacy evaluation according to the results from drug 30 
release and skin permeation experiments. For instance, gels 1·betamethasone or 1·triamcinolone or 31 
1·tacrolimus or 1·methotrexate or 1·2Br (containing no drug), were applied in groups of mice to evaluate 32 
their anti-hyperplasia and anti-inflammatory activity. As well, drugs in solution, and the cream Celecrem® 33 
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containing betamethasone 17-valerate, as a reference marketed product, were applied for comparison 1 
purposes. The gel 1·gemcitabine was not studied in vivo as it showed the lowest drug retention beneath the 2 
skin and it did not show permeation. A group of mice with daily TPA but without further treatment was taken 3 
as Control (psoriatic skin). The increase in ear thickness was plotted relative to the increase observed in 4 
psoriatic skin (Figure 7), and the main signs at the macroscopic level were observed (Figure 8).  5 
As it can be seen by comparing healthy and psoriatic skin values, the daily TPA application leads to a 6 
gradual and significant increase in ear thickness (P<0.001) (Figure 7, A-F), and a gradual occurrence of 7 
roughness, desquamation, hair loss, and change of skin color, confirming the induced psoriasiform 8 
hyperplasia through the in-vivo model applied (Figure 8, B).  9 
Gel 1·2Br (without drug) shows to be majorly innocuous on healthy skin, as after 10-day application, it 10 
does not induce an increase in thickness (Figure 7, A), though a moderate exudate could be observed in tissue 11 
at day 11 (Figure 8, C). On the other hand, gel 1·2Br without any drug, decreases on 25% the hyperplasia 12 
induced by TPA application, though it cannot be considered a significant difference (P<0.05) (Figure 7, A), 13 
and the signs observed do not represent an improvement as compared to psoriatic skin (Figure 8, D). 14 
 15 
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Figure 7. Ear thickness increase (both in absolute values [mm/left axis] and relative to psoriatic skin [%/right axis]) of mice along 10-day application of TPA 1 
and a treatment. (A-F) TPA application without further treatment was taken as psoriatic skin, while ears with neither TPA nor treatment were taken as healthy skin. 2 
(A) 1·2Br (both on healthy and psoriatic skin). (B) Betamethasone 17-valerate solution, gel 1·betamethasone, and Celecrem® (containing betamethasone 17-3 
valerate). (C) Tacrolimus solution and gel 1·tacrolimus. (D) Triamcinolone acetonide solution and gel 1·triamcinolone. (E) Methotrexate sodium salt solution 4 
and gel 1·methotrexate. (F) Ear thickness increase at day 11 (overall view). Values represent Means±SD (n=6). *Significant difference versus psoriatic skin 5 
(P<0.05). 6 
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Figure 8. Macroscopic ear tissue observations at days 5, 8 and 11 along application of TPA and a treatment. (A) Left ear with ethanol but no further treatment 1 
was taken as healthy skin. (B) Right ear stimulated with TPA but with no further treatment was taken as psoriatic skin. (C) Right ear without TPA stimulation 2 
(healthy skin) and treated with gel 1·2Br. (D-M) Right ear stimulated with TPA and a treatment, either (D) gel 1·2Br without drug, (E) the marketed cream 3 
Celecrem® containing Betamethasone 17-valerate, (F) Betamethasone 17-valerate in solution, (G) gel 1·betamethasone, (H) Triamcinolone acetonide in solution, 4 
(I) gel 1·triamcinolone, (J) tacrolimus solution, (K) gel 1·tacrolimus, (L) methotrexate sodium salt solution, or (M) gel 1·methotrexate. 5 
The commercially available Celecrem®, containing betamethasone 17-valerate, was tested as the reference 6 
product for comparison purposes, which showed a significant 85% decrease in ear thickness (P<0.001) 7 
(Figure 7, B), though it could not prevent the vasculature alterations and blood marks up to day 8, but it 8 
restored the normal vasculature at day 11 (Figure 8, E), confirming the efficacy of the commercial treatment. 9 
Similarly, the application of betamethasone 17-valerate in acetone solution showed a 95% thickness decrease, 10 
also showing vasculature alterations at the macroscopic level (Figure 8, F), while the application of 11 
betamethasone 17-valerate in gel (1·betamethasone), lead to the highest efficacy showing thickness decrease 12 
even below the basal values (Figure 7, B). Though no significant difference is observed as compared to the 13 
commercial product, this slightly higher efficacy might be related to the higher permeation and higher 14 
retention observed from gel 1·betamethasone as compared to the marketed product [26].  15 
Similar increased efficacies can be observed when other drugs are incorporated in gel 1·2Br. For instance, 16 
the drug tacrolimus in solution did not show a significant thickness decrease (9%); however, when it is 17 
incorporated in gel (1·tacrolimus), a 50% decrease can be observed (P<0.05) (Figure 7, C). This is in 18 
accordance with the macroscopic observations, where the mice treated with tacrolimus in solution gradually 19 
showed hair loss and the desquamation observed in psoriatic skin (Figure 8, J), while the mice treated with 20 
gel 1·tacrolimus showed moderately altered vasculature but no hair loss and desquamation (Figure 8, K).  21 
As well, the application of triamcinolone acetonide in solution, which is also corticoid drug, only lead to a 22 
35% thickness decrease (P>0.05); nonetheless, the treatment with gel 1·triamcinolone results in 95% 23 
decrease (P<0.001) (Figure 7, D). Similarly, the macroscopic observations of mice treated with triamcinolone 24 
acetonide in solution show some vasculature alterations, ear rigidity, and a complete hair loss at day 11 25 
(Figure 8, H), while the mice treated with gel 1·triamcinolone only show rigidity but no hair loss (Figure 8, 26 
I). These results also correlate with the skin permeation and retention experiments, where tacrolimus and 27 
both corticoid drugs triamcinolone acetonide and betamethasone 17-valerate, after topical application, are 28 
highly retained inside the skin, where they perform their therapeutic activity. 29 
Finally, the treatment with methotrexate sodium salt solution appears to decrease in 50% the ear thickness 30 
only at day 11, while the application of gel 1·methotrexate shows a similar decrease already from day 8, 31 
and which is maintained until day 11 (Figure 7, D), suggesting a promoted drug permeation or retention 32 
inside the skin by the supramolecular gel. This increased efficacy can also be seen at the macroscopic tissue 33 
observations as the application of the drug in solution lead to rigidity, complete hair loss and exudate from 34 
day 8, while the application of gel 1·methotrexate induced ear rigidity, but neither hair loss nor exudate. 35 
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CONCLUSION 1 
In this work, the gelling ability of a dicationic bis-imidazolium amphiphile 1·2Br has been proven to be 2 
effective when structurally diverse drugs, including compounds with different charge and lipophilicity, and 3 
which are used in the treatment of Psoriasis, were incorporated into the mixture. Hydrogels can be 4 
spontaneously formed in only 10 min in presence of only ethanol and water. A nucleation enhancement of 5 
the gelation process was observed with low concentrations of either methotrexate sodium salt or tacrolimus 6 
or triamcinolone acetonide, as gel formation time is decreased; however, the further increase in drug 7 
concentration increases gelation time. The fibrous structure of the gels at the nanoscale is influenced by the 8 
drug included. Interestingly, when the gel is formed in presence of gemcitabine hydrochloride, no apparent 9 
drug precipitates can be found in xerogels as observed by SEM, suggesting a nanoscaled precipitation, which 10 
is optimum for biopharmaceutical purposes. The structural differences of the xerogels can be also correlated 11 
with their viscoelastic properties, where the gel showing more network entanglement (1·methotrexate) 12 
presented both the highest resistances to rupture and to deformation. Nonetheless, all the formulations could 13 
be categorized as soft solid-like gels, which can break abruptly when critical stress is reached, and therefore 14 
optimum for application over irritated skin such as that in Psoriasis. Gels can incorporate drugs not only 15 
dissolved at the interstitial space, but also 72% of either gemcitabine or methotrexate, and 38% of tacrolimus, 16 
are found within their fibers when gels are formed at a 1:1 molar ratio. This unique fiber-incorporation 17 
behavior acts as a packaging that protects the drug, and importantly, influences a Two-Phase Exponential 18 
drug release profile, in which the first phase corresponds to the drug dissolved in the interstitial space of the 19 
gel, and the second phase corresponds to the drug exiting from the fibers. The release kinetics of each phase 20 
is related with the physicochemical properties of the drugs, where the speed in the first phase is promoted by 21 
low or moderate log P values and moderate or high water solubilities, while the speed in the second phase is 22 
promoted by moderate to high log P values but also moderate to high water solubilities. As a result, highly 23 
hydrophilic drugs such as gemcitabine hydrochloride show a fast release in the first phase but a slow sustained 24 
release in the second phase; highly hydrophobic drugs such as tacrolimus are released at a moderate speed in 25 
both phases; whereas drugs with moderate hydrophobicity such as betamethasone 17-valerate and 26 
triamcinolone acetonide are rapidly released in both phases.)  27 
Moreover, skin permeation tests show the complete permeation of betamethasone 17-valerate, 28 
triamcinolone acetonide and methotrexate, while all the drugs (including gemcitabine and tacrolimus), after 29 
application, are retained inside the skin, where they perform they therapeutic activity. In addition, the 30 
application of 1·methotrexate leads to drug concentrations in plasma fairly below the toxic ones, for which 31 
the application of this gel can be considered safe for other parts of the body. Finally, in vivo studies show 32 
that the application of these gels incorporating a drug successfully prevent the typical hyperplasia and tissue 33 
degeneration observed in Psoriasis (P<0.01), especially in the cases of 1·triamcinolone and 34 
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1·betamethasone, which completely prevent the skin thickness increase. These two gels also show slightly 1 
improved efficacies as compared to the commercial product Celecrem® containing betamethasone 17-2 
valerate. Moreover, the incorporation of the drugs in these gels seems to promote the efficacy as compared 3 
to the drugs in acetone solution, both at the anti-hyperplasia activity and at preventing tissue degeneration, a 4 
behavior that could be related to the retention of the drug beneath the skin promoted by the gel.  5 
The topical application of these gels shows to be an interesting option in the treatment of skin diseases such 6 
as Psoriasis, avoiding the first pass metabolism associated with oral dosages, and increasing the drug 7 
concentration at the pharmacological target, while their great versatility and ease of preparation provides 8 
great scalability for industrial commercialization. 9 
 10 
SUPPORTING INFORMATION AVAILABLE 11 
Frequency sweep tests (Figure S 1), 1H-NMR spectra from drug incorporation studies (Figure S 2 - Figure 12 
S 4), SEM images of drug precipites previously in solution (Figure S 5), Drug release parameters (Table S 13 
1), Physicochemical properties of drugs under study (Table S 2), Skin permeation parameters (Table S 3), 14 
Statistical analysis of Kp values (Table S 4), Evaluation of 1·methotrexate systemic toxicity (Table S 5), 15 
Drug retention inside the skin with statistical analysis (Table S 6 and Table S 7), and statistical analysis of in 16 
vivo experiments (Table S 8), are available and can be found in Supporting Information. 17 
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Rheological studies 
 
Figure S 1. Elastic modulus (G’) and loss modulus (G’’) as a function of stress frequency for samples: (A) 1·2Br (B) 1·gemcitabine, (C) 1·tacrolimus and (D) 
1·methotrexate. 
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Drug incorporation studies 
 
Figure S 2. 1H NMR spectra corresponding to the incorporation of gemcitabine hydrochloride within the gel. 
A) Tube A, Record 1: gemcitabine hydrochloride (8.28 μmol) dissolved in 0.75 mL of deuterium oxide.  
B) Tube A, Record 2: after addition of 1·2Br (8.28 μmol) in 0.75 mL of deuterated methanol. 
C) Tube B, Record 1: gemcitabine hydrochloride (8.28 μmol) dissolved in 0.75 mL of deuterium oxide. 
D) Tube B, Record 2: after addition of 0.75 mL of deuterated methanol.   
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Figure S 3. . 1H NMR spectra corresponding to the incorporation of methotrexate sodium salt within the gel. 
A) Tube A, Record 1: Methotrexate sodium salt (8.28 μmol) dissolved in 0.75 mL of deuterium oxide.  
B) Tube A, Record 2: after addition of 1·2Br (8.28 μmol) in 0.75 mL of deuterated methanol. 
C) Tube B, Record 1: Methotrexate sodium salt (8.28 μmol) dissolved in 0.75 mL of deuterium oxide. 
D) Tube B, Record 2: after addition of 0.75 mL of deuterated methanol.  
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Figure S 4. 1H NMR spectra corresponding to the incorporation of tacrolimus within the gel. 
A) Tube A, Record 1: tacrolimus (8.28 μmol) dissolved in 0.75 mL of deuterated methanol.  
B) Tube A, Record 2: after dissolving 1·2Br (8.28 μmol) in Tube A and adding 0.75 mL of deuterium oxide. 
C) Tube B, Record 1: tacrolimus (8.28 μmol) dissolved in 0.75 mL of deuterated methanol.  
D) Tube B, Record 2: after addition of 0.75 mL of deuterium oxide.  
Tube A
Tube A
Tube B
Tube B
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Microscopy 
 
 
Figure S 5. SEM images of drug precipitates of gemcitabine hydrochloride (A), tacrolimus (B), and methotrexate sodium salt (C), previously in a 2.5 mg/mL 
solution in ethanol:water (50:50) without gelator. Scalebar represents 5 µm. 
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Drug release studies 
 
Table S 1. Drug release parameters from gels under study.  
 
1·gemcitabine 1·tacrolimus 1·methotrexate 1·triamcinolonea 1·betamethasonea 
Model Two Phase 
Exponential 
Association 
Two Phase 
Exponential 
Association 
Two Phase 
Exponential 
Association 
One Phase 
Exponential 
Association 
Two Phase 
Exponential 
Association 
One Phase 
Exponential 
Association 
Two Phase 
Exponential 
Association 
YMAX1 (%) 59.1 ± 0.9 31.0 ± 48.3 41.4 ± 1.7 90.9 ± 1.60 74 79.2 ± 3.14 66 
K1 (h-1) 0.4 ± 0.01 0.1 ± 0.12 0.4 ± 0.04 0.2 ± 0.02 0.25 0.3 ± 0.04 0.3 
YMAX2 (%) 209.2 ± 214.6 209.7 ± 186.4 185.4 ± 163.0  17  13 
K2 (h-1) 0.0002 ± 0.0220 0.0011 ± 0.1116 0.0010 ± 0.0094  0.25  0.3 
R² 0.9999 0.9918 0.9994 0.9965 0.9964 0.9832 0.9816 
aData taken from [26] 
 
Drug physicochemical properties 
 
Table S 2. Physicochemical properties of drugs betamethasone 17-valerate, triamcinolone acetonide, gemcitabine, tacrolimus and methotrexate sodium salt. 
Drug Log P  MW 
Solubility 
in water 
(mg/L) 
Ref. 
Betamethasone 17-valerate 3.57 476.6 9.3 [64,65] 
Triamcinolone acetonide 2.5 434.5 20.9 [66] 
Tacrolimus 3.19 to 5.59 804.0 1.82e-2 [53,67,68] 
Gemcitabine -1.4 to -1.24 263.2 5.13e4 [69–71] 
Methotrexate sodium salt -1.85 to -0.5 454.4 2.6e3 [72–74] 
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Skin permeation studies 
1) Skin permeation parameters 
Table S 3. Skin permeation parameters from drugs upon application of gels 1·betamethasone, 1·triamcinolone and 1·methotrexate on human skin. Values 
represent the calculated parameters ± SD (n=5). 
Parameters 
1·betamethasone 1·triamcinolone 1·methotrexate 
Jss (µg cm-2 h-1) 0.391±0.066 0.306±0.047 0.045±0.005 
Tlag (h) 4.64 10.61 10.60 
C0 (mg cm
-3) 5 5 2.5 
Kp · 103 (cm h-1)  0.078±0.013 0.061±0.009 0.018±0.002 
 
 
Table S 4. One-way Analysis of Variance with Tukey’s multiple comparison test of Kp values obtained from skin permeation of gels 1·betamethasone, 
1·triamcinolone and 1·methotrexate. 
Parameter Value    
One-way analysis of variance     
  P value P<0.0001    
  P value summary ***    
  Are means signif. different? (P < 0.05) Yes    
  Number of groups 3    
  F 53,79    
  R squared 0,8997    
Bartlett's test for equal variances     
  Bartlett's statistic (corrected) 8,343    
  P value 0,0154    
  P value summary *    
  Do the variances differ signif. (P < 0.05) Yes    
ANOVA Table SS df MS  
  Treatment (between columns) 0,009571 2 0,004786  
  Residual (within columns) 0,001068 12 0,00008896  
  Total 0,01064 14   
Tukey's Multiple Comparison Test Mean Diff. q P value 95% CI of diff 
  1·betamethasone vs 1·triamcinolone 0,01702 4,035 P < 0.05 0.001105 to 0.03294 
  1·betamethasone vs 1·methotrexate 0,06003 14,23 P < 0.001 0.04411 to 0.07594 
  1·triamcinolone vs 1·methotrexate 0,04301 10,20 P < 0.001 0.02709 to 0.05892 
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2) Prediction of systemic toxicity of gel 1·methotrexate 
A possible systemic toxicity from the topical application of 1·methotrexe was estimated by means of the 
plasmatic drug concentration at steady state (Css). Css is calculated by means of the following equation: 
𝐶𝑆𝑆 =  
𝐽𝑆𝑆  ·  𝑆𝐴𝑇𝑎𝑟𝑒𝑎
𝐶𝐿𝑃
 
where SATarea is the hypothetical area of topical application (e.g. 10 cm
2) and CLp corresponds to the 
methotrexate sodium salt plasmatic clearance. It is reported that methotrexate sodium salt plasmatic clearance 
presents a strong variability,[58,75–78] so an indicative median value of 5.5 L h-1 was used. 
 
Table S 5. Calculated methotrexate plasma concentration at steady state (Css) upon topical application of gel 1·methotrexate.and determination of the systemic 
toxicity. aHypothetical area for dermal application. bPlasmatic clearance of methotrexate is reported to have a great variability. A median value of 5.5 L h-1 is taken. 
cReported plasmatic concentration that shows systemic toxicity. 
 1·methotrexate 
Css (µg L-1) 0.086 
SATarea (cm
2)a 10 
CLP (L h
-1)b 5.5 
Toxicity systemic concentration (M)c 3·10-6 
Toxicity systemic concentration (µg cm-3)c 1.36 
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3) Drug retention inside the skin 
By means of both extraction and recovery experimental results, the real amount of drug that remained inside 
the skin after the permeation studies can be calculated  
 
𝑄𝑟𝑒𝑡 =
𝑄𝑒𝑥𝑡
(𝑅 · 𝑊𝑠𝑘𝑖𝑛 ·  𝐴𝑝𝑒𝑟 )
  
where Qret is quantity of drug retained into the skin, Qext is the amount that was possible to be extracted 
from the skin, R is the recovery factor (the fraction of drug that can be extracted out of the total amount of 
drug that is actually retained), Aper is the area of permeation (2.54 cm
2) and Wskin corresponds to the weight 
of each skin permeated section. 
 
Table S 6. Drug recovery factors and calculated amount of drug retained inside the skin after permeation experiments with gels 1·betamethasone, 
1·triamcinolone, 1·gemcitabine, 1·tacrolimus and 1·methotrexate. Drug retained is expressed in µg of drug per gram and square centimeter of skin ± SD. 
Drug Recovery factor (R) 
Drug retained 
(µg g-1 cm-2) 
Betamethasone 17-valerate 0.27 31.6 ± 7.9 
Triamcinolone acetonide 0.09 605.4 ± 182.5 
Gemcitabine 0.31 198.1 ± 27.9 
Tacrolimus 0.36 269.4 ± 211.2 
Methotrexate 0.28 61.5 ± 11.1 
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Table S 7. One-way ANOVA with Tukey’s multiple comparison test from the amount of drug retained values. 
One-way analysis of variance     
  P value P<0.0001    
  P value summary ***    
  Are means signif. different? (P < 0.05) Yes    
  Number of groups 5    
  F 16,73    
  R squared 0,7700    
Bartlett's test for equal variances     
  Bartlett's statistic (corrected) 42,19    
  P value P<0.0001    
  P value summary ***    
  Do the variances differ signif. (P < 0.05) Yes    
ANOVA Table SS df MS  
  Treatment (between columns) 1056000 4 264000  
  Residual (within columns) 315600 20 15780  
  Total 1372000 24   
     
Tukey's Multiple Comparison Test Mean Diff. q P value 95% CI of diff 
  1·betamethasone vs 1·triamcinolone -573,8 10,21 P < 0.001 -811.6 to -336.1 
  1·betamethasone vs 1·gemcitabine -166,5 2,965 P > 0.05 -404.3 to 71.20 
  1·betamethasone vs 1·tacrolimus -238,2 4,240 P < 0.05 -475.9 to -0.4704 
  1·betamethasone vs 1·methotrexate -29,91 0,5324 P > 0.05 -267.6 to 207.8 
  1·triamcinolone vs 1·gemcitabine 407,3 7,250 P < 0.001 169.5 to 645.0 
  1·triamcinolone vs 1·tacrolimus 335,6 5,974 P < 0.01 97.88 to 573.3 
  1·triamcinolone vs 1·methotrexate 543,9 9,682 P < 0.001 306.2 to 781.6 
  1·gemcitabine vs 1·tacrolimus -71,67 1,276 P > 0.05 -309.4 to 166.1 
  1·gemcitabine vs 1·methotrexate 136,6 2,432 P > 0.05 -101.1 to 374.4 
  1·tacrolimus vs 1·methotrexate 208,3 3,708 P > 0.05 -29.44 to 446.0 
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In-vivo experiments 
 
Table S 8. One-way ANOVA with Tukey’s multiple comparison test from the ear thickness increase values at day 11 after TPA and treatment application. 
One-way analysis of variance     
P value < 0.0001      
P value summary ***      
Are means signif. different? (P < 0.05) Yes      
Number of groups 13      
F 17,47      
R squared 0,7718      
       
ANOVA Table SS df MS    
Treatment (between columns) 1,597 12 0,1331    
Residual (within columns) 0,4722 62 0,007616    
Total 2,069 74     
Tukey's Multiple Comparison Test Mean Diff. q 
Significant? P 
< 0.05? Summary 95% CI of diff 
Healthy skin (Control(-)) vs Psoriatic skin (Control(+)) -0,3900 8,938 Yes *** -0.6027 to -0.1773 
Healthy skin (Control(-)) vs 1·2Br (healthy skin) -0,0100 0,2292 No ns -0.2227 to 0.2027 
Healthy skin (Control(-)) vs 1·2Br (psoriatic skin) -0,2900 6,646 Yes ** -0.5027 to -0.07729 
Healthy skin (Control(-)) vs Celecrem -0,0400 0,9167 No ns -0.2527 to 0.1727 
Healthy skin (Control(-)) vs Tacrolimus -0,3400 7,792 Yes *** -0.5527 to -0.1273 
Healthy skin (Control(-)) vs 1·tacrolimus -0,2700 6,188 Yes ** -0.4827 to -0.05729 
Healthy skin (Control(-)) vs Betamethasone 0,0100 0,2292 No ns -0.2027 to 0.2227 
Healthy skin (Control(-)) vs 1·betamethasone 0,0400 0,9167 No ns -0.1727 to 0.2527 
Healthy skin (Control(-)) vs Triamcinolone -0,2500 5,729 Yes ** -0.4627 to -0.03729 
Healthy skin (Control(-)) vs 1·triamcinolone 0,0000 0,0000 No ns -0.2127 to 0.2127 
Healthy skin (Control(-)) vs Methotrexate -0,1800 4,125 No ns -0.3927 to 0.03271 
Healthy skin (Control(-)) vs 1·methotrexate -0,1700 3,896 No ns -0.3827 to 0.04271 
Psoriatic skin (Control(+)) vs 1·2Br (healthy skin) 0,3800 10,67 Yes *** 0.2063 to 0.5537 
Psoriatic skin (Control(+)) vs 1·2Br (psoriatic skin) 0,1000 2,807 No ns -0.07368 to 0.2737 
Psoriatic skin (Control(+)) vs Celecrem 0,3500 9,824 Yes *** 0.1763 to 0.5237 
Psoriatic skin (Control(+)) vs Tacrolimus 0,05000 1,403 No ns -0.1237 to 0.2237 
Psoriatic skin (Control(+)) vs 1·tacrolimus 0,1200 3,368 No ns -0.05368 to 0.2937 
Psoriatic skin (Control(+)) vs Betamethasone 0,4000 11,23 Yes *** 0.2263 to 0.5737 
Psoriatic skin (Control(+)) vs 1·betamethasone 0,4300 12,07 Yes *** 0.2563 to 0.6037 
Psoriatic skin (Control(+)) vs Triamcinolone 0,1400 3,929 No ns -0.03368 to 0.3137 
Psoriatic skin (Control(+)) vs 1·triamcinolone 0,3900 10,95 Yes *** 0.2163 to 0.5637 
Psoriatic skin (Control(+)) vs Methotrexate 0,2100 5,894 Yes ** 0.03632 to 0.3837 
Psoriatic skin (Control(+)) vs 1·methotrexate 0,2200 6,175 Yes ** 0.04632 to 0.3937 
1·2Br (healthy skin) vs 1·2Br (psoriatic skin) -0,2800 7,859 Yes *** -0.4537 to -0.1063 
1·2Br (healthy skin) vs Celecrem -0,0300 0,8420 No ns -0.2037 to 0.1437 
1·2Br (healthy skin) vs Tacrolimus -0,3300 9,262 Yes *** -0.5037 to -0.1563 
1·2Br (healthy skin) vs 1·tacrolimus -0,2600 7,298 Yes *** -0.4337 to -0.08632 
1·2Br (healthy skin) vs Betamethasone 0,0200 0,5614 No ns -0.1537 to 0.1937 
1·2Br (healthy skin) vs 1·betamethasone 0,0500 1,403 No ns -0.1237 to 0.2237 
1·2Br (healthy skin) vs Triamcinolone -0,2400 6,736 Yes *** -0.4137 to -0.06632 
1·2Br (healthy skin) vs 1·triamcinolone 0,0100 0,2807 No ns -0.1637 to 0.1837 
1·2Br (healthy skin) vs Methotrexate -0,1700 4,772 No ns -0.3437 to 0.003678 
1·2Br (healthy skin) vs 1·methotrexate -0,1600 4,491 No ns -0.3337 to 0.01368 
1·2Br (psoriatic skin) vs Celecrem 0,2500 7,017 Yes *** 0.07632 to 0.4237 
1·2Br (psoriatic skin) vs Tacrolimus -0,05000 1,403 No ns -0.2237 to 0.1237 
1·2Br (psoriatic skin) vs 1·tacrolimus 0,02000 0,5614 No ns -0.1537 to 0.1937 
1·2Br (psoriatic skin) vs Betamethasone 0,3000 8,420 Yes *** 0.1263 to 0.4737 
1·2Br (psoriatic skin) vs 1·betamethasone 0,3300 9,262 Yes *** 0.1563 to 0.5037 
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1·2Br (psoriatic skin) vs Triamcinolone 0,04000 1,123 No ns -0.1337 to 0.2137 
1·2Br (psoriatic skin) vs 1·triamcinolone 0,2900 8,140 Yes *** 0.1163 to 0.4637 
1·2Br (psoriatic skin) vs Methotrexate 0,1100 3,087 No ns -0.06368 to 0.2837 
1·2Br (psoriatic skin) vs 1·methotrexate 0,1200 3,368 No ns -0.05368 to 0.2937 
Celecrem vs Tacrolimus -0,3000 8,420 Yes *** -0.4737 to -0.1263 
Celecrem vs 1·tacrolimus -0,2300 6,456 Yes ** -0.4037 to -0.05632 
Celecrem vs Betamethasone 0,0500 1,403 No ns -0.1237 to 0.2237 
Celecrem vs 1·betamethasone 0,0800 2,245 No ns -0.09368 to 0.2537 
Celecrem vs Triamcinolone -0,2100 5,894 Yes ** -0.3837 to -0.03632 
Celecrem vs 1·triamcinolone 0,0400 1,123 No ns -0.1337 to 0.2137 
Celecrem vs Methotrexate -0,1400 3,929 No ns -0.3137 to 0.03368 
Celecrem vs 1·methotrexate -0,1300 3,649 No ns -0.3037 to 0.04368 
Tacrolimus vs 1·tacrolimus 0,07000 1,965 No ns -0.1037 to 0.2437 
Tacrolimus vs Betamethasone 0,3500 9,824 Yes *** 0.1763 to 0.5237 
Tacrolimus vs 1·betamethasone 0,3800 10,67 Yes *** 0.2063 to 0.5537 
Tacrolimus vs Triamcinolone 0,0900 2,526 No ns -0.08368 to 0.2637 
Tacrolimus vs 1·triamcinolone 0,3400 9,543 Yes *** 0.1663 to 0.5137 
Tacrolimus vs Methotrexate 0,1600 4,491 No ns -0.01368 to 0.3337 
Tacrolimus vs 1·methotrexate 0,1700 4,772 No ns -0.003678 to 0.3437 
1·tacrolimus vs Betamethasone 0,2800 7,859 Yes *** 0.1063 to 0.4537 
1·tacrolimus vs 1·betamethasone 0,3100 8,701 Yes *** 0.1363 to 0.4837 
1·tacrolimus vs Triamcinolone 0,02000 0,5614 No ns -0.1537 to 0.1937 
1·tacrolimus vs 1·triamcinolone 0,2700 7,578 Yes *** 0.09632 to 0.4437 
1·tacrolimus vs Methotrexate 0,09000 2,526 No ns -0.08368 to 0.2637 
1·tacrolimus vs 1·methotrexate 0,1000 2,807 No ns -0.07368 to 0.2737 
Betamethasone vs 1·betamethasone 0,0300 0,8420 No ns -0.1437 to 0.2037 
Betamethasone vs Triamcinolone -0,2600 7,298 Yes *** -0.4337 to -0.08632 
Betamethasone vs 1·triamcinolone -0,0100 0,2807 No ns -0.1837 to 0.1637 
Betamethasone vs Methotrexate -0,1900 5,333 Yes * -0.3637 to -0.01632 
Betamethasone vs 1·methotrexate -0,1800 5,052 Yes * -0.3537 to -0.006322 
1·betamethasone vs Triamcinolone -0,2900 8,140 Yes *** -0.4637 to -0.1163 
1·betamethasone vs 1·triamcinolone -0,0400 1,123 No ns -0.2137 to 0.1337 
1·betamethasone vs Methotrexate -0,2200 6,175 Yes ** -0.3937 to -0.04632 
1·betamethasone vs 1·methotrexate -0,2100 5,894 Yes ** -0.3837 to -0.03632 
Triamcinolone vs 1·triamcinolone 0,2500 7,017 Yes *** 0.07632 to 0.4237 
Triamcinolone vs Methotrexate 0,07000 1,965 No ns -0.1037 to 0.2437 
Triamcinolone vs 1·methotrexate 0,08000 2,245 No ns -0.09368 to 0.2537 
1·triamcinolone vs Methotrexate -0,1800 5,052 Yes * -0.3537 to -0.006322 
1·triamcinolone vs 1·methotrexate -0,1700 4,772 No ns -0.3437 to 0.003678 
Methotrexate vs 1·methotrexate 0,01000 0,2807 No ns -0.1637 to 0.1837 
 
